89bio, Inc.
DelistedCIK 1785173fmd_110V6DT1XR6NXRBNVMT6WBC9VFManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Jun 30, 2025, 30 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Realized investment gains (losses) | – | 0 | – | 0 | – | – |
| Research and development | 21 | 36 | 70 | 81 | 122 | 345 |
| Total operating expenses | 27 | 49 | 90 | 102 | 151 | 385 |
| Operating income | (27) | (49) | (90) | (102) | (151) | (385) |
| Interest expense | – | – | 1 | 2 | 5 | 5 |
| Interest and investment income | – | – | 0 | 2 | – | – |
| Other non-operating income (expense) | (31) | (0) | 0 | 2 | 18 | 24 |
| Income before taxes | (57) | (50) | (90) | (102) | (138) | (366) |
| Income tax expense | 0 | (0) | (0) | 0 | 4 | 1 |
| Net income from continuing operations | (57) | (49) | (90) | (102) | (142) | (367) |
| Net income | (57) | (49) | (90) | (102) | (142) | (367) |